Pharmacological therapy of spondyloarthritis

Palazzi, Carlo; D’Angelo, Salvatore; Gilio, Michele; Leccese, Pietro; Padula, Angela; Olivieri, Ignazio

doi:10.1517/14656566.2015.1052744

Cited by 13 publications

(7 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of IBD and rheumatologic musculoskeletal complications are similar to the treatment of IBD itself (using 5-ASA combinations like Sulfasalazine), but the question is, does IBD treatment affects MSK? [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

From bowel inflammation to the bone and joints: musculoskeletal examination in inflammatory bowel disease (IBD)

Tavassoli

Shahabinasab

Norouzi

et al. 2021

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background One of the most important complications in inflammatory Bowel Disease (IBD) are musculoskeletal manifestations that are reported in more than 50% of patients. Objectives In this study, we aimed to evaluate the musculoskeletal and radiologic manifestations in our IBD patients. Methods In this cross-sectional study on 96 mild-to-moderate IBD patients (76 UC, 18 CD and 2 undifferentiated IBD) with mean (SD) age of 39.28 (11.42) years, 44 (45.8%) were males and 52 were (54.2%) females. Patients were examined by an expert rheumatologist and their musculoskeletal symptoms were assessed. The musculoskeletal system was evaluated by Modified Schober test, Thoracic expansion (TE), Occiput to wall distance (OWD), and Patrick’s or FABER test. Peripheral joints were also examined in all four extremities. Then patients were referred for pelvic and lumbosacral x-ray. Sacroiliitis grading was performed using the New York criteria. Results Inflammatory low back pain was reported in 5 (5.2%), enthesopathy in 6 (6.5%) and dactylitis in 1 (1.1%). Positive Schober test was recorded in 5 (5.2%) and Patrick test in 3 (3.1%). Forty-nine (51%) cases had normal imaging with no sacroiliitis, endplate sclerosis was seen in 33 cases (34.4%), grade 3 and grade 4 were seen in 10 cases (10.4%). Conclusions In the present study, 34.4% of the IBD patients had mild radiologic changes as endplate sclerosis and 95% had a normal physical examination.

show abstract

Section: Introductionmentioning

confidence: 99%

From bowel inflammation to the bone and joints: musculoskeletal examination in inflammatory bowel disease (IBD)

Tavassoli

Shahabinasab

Norouzi

et al. 2021

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…The treatment of IBD and rheumatologic musculoskeletal complications are similar to the treatment of IBD itself (using 5-ASA combinations like Sulfasalazine), but immunosuppressives are used in retractable musculoskeletal pain, although they may worsen the course of the bowel disease (12)(13).…”

Section: Introductionmentioning

confidence: 99%

From Bowel inflammation to the Bone and Joints: Rheumatologic examination in Inflammatory Bowel Disease (IBD)

Tavassoli

Mirkamali

Shahabinasab

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The most common complications in inflammatory Bowel Disease (IBD) are musculoskeletal manifestations that are reported in more than 50% of patients. Objectives: In this study, we aimed to evaluate the musculoskeletal and radiologic manifestations in our IBD patients.Methods: In this study on 96 mild-to-moderate IBD patients (76 UC, 18 CD and 2 undifferentiated IBD) with mean (SD) age of 39.28 (11.42) years, 44 (45.8%) were males and 52 were (54.2%) females. Patients were examined by an expert rheumatologist and their musculoskeletal symptoms were assessed. The musculoskeletal system was evaluated by Modified Schober test, Thoracic expansion (TE), Occiput to wall distance (OWD), and Patrick's or FABER test. Peripheral joints were also examined in all four extremities. Then patients were referred for pelvic and lumbosacral x-ray. Sacroiliitis grading was performed using the New York criteria. Results: Inflammatory low back pain was reported in 5 (5.2%), enthesopathy in 6 (6.5%) and dactilitis in 1 (1.1%). Positive Schober test was recorded in 5 (5.2%) and Patrick test in 3 (3.1%). Forty-nine (51%) cases had normal imaging with no sacroilliitis, endplate sclerosis was seen in 33 cases (34.4%), grade 3 and grade 4 were seen in 10 cases (10.4%). Conclusions: In the present study, 34.4% of the IBD patients had mild radiologic changes as endplate sclerosis and 95% had a normal physical examination.

show abstract

“…As per the recently updated treatment recommendations (2016) from ASAS and the European League Against Rheumatism,7 NSAIDs and physical therapy have been recommended as first-line treatment for AS; however, the disease becomes refractory to these agents over time 8–10. The use of anti-tumor necrosis factor (anti-TNF) biologics or IL-17A inhibitor is recommended in axial spondyloarthritis after the failure of NSAIDs.…”

Section: Introductionmentioning

confidence: 99%

<p>Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland</p>

Purmonen¹,

Puolakka²,

Mishra³

et al. 2019

CEOR

View full text Add to dashboard Cite

This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. Methods: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pegol, etanercept, etanercept biosimilar, golimumab, and infliximab in a biologic-naïve population over a lifetime horizon. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess the treatment response. Efficacy inputs were obtained from the network meta-analysis, and other model inputs were obtained from the published literature and Finnish sources. Main study outcomes included quality-adjusted life years (QALYs) gained and incremental cost-effectiveness ratio in terms of cost per QALY gained. Robustness of results was confirmed by sensitivity analyses and alternative scenario analyses. Results: Secukinumab achieved highest QALYs (13.1) at lowest expected lifetime cost (€279,872) vs other comparators in biologic-naïve AS patients in the base case analysis, thus it dominated other biologics. Golimumab had a second highest QALYs (12.9) at the total cost of €309,551. Results were sensitive to variation in BASDAI 50 response for secukinumab, baseline Bath Ankylosing Spondylitis Functional Index (BASFI) score across all drugs, change in BASDAI and BASFI scores, and discount rates as observed in the one-way sensitivity analyses. Secukinumab was either dominant or cost-effective treatment in different alternative scenarios. Conclusion: Secukinumab presented itself to be the dominant (ie, less costly and more effective) treatment vs other comparators for the biologic-naïve patients with AS in Finland.

show abstract

Pharmacological therapy of spondyloarthritis

Cited by 13 publications

References 114 publications

From bowel inflammation to the bone and joints: musculoskeletal examination in inflammatory bowel disease (IBD)

From bowel inflammation to the bone and joints: musculoskeletal examination in inflammatory bowel disease (IBD)

From Bowel inflammation to the Bone and Joints: Rheumatologic examination in Inflammatory Bowel Disease (IBD)

<p>Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland</p>

Contact Info

Product

Resources

About